A Rare HBV Subgenotype D4 with Unique Genomic Signatures Identified in North-Eastern India – An Emerging Clinical Challenge?

Priyanka Banerjee¹, Rajiv Kumar Mondal¹, Madhuparna Nandi¹, Sumantra Ghosh¹, Mousumi Khatun¹, Nabendu Chakraborty², Swatilekha Bhattacharya², Arindam RoyChoudhury³, Soma Banerjee¹, Amal Santra³, Samir Sil⁴, Abhijit Chowdhury⁵, Pradip Bhaumik², Simanti Datta¹*

¹Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India, ²Agartala Government Medical College, Tripura, India, ³Columbia University, New York, New York, United States of America, ⁴Tripura University, Tripura, India, ⁵Department of Hepatology, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India

Abstract

Background/Aims: HBV has been classified into ten genotypes (A–J) and multiple subgenotypes, some of which strongly influence disease outcome and their distribution also correlate with human migration. HBV infection is highly prevalent in India and its diverse population provides an excellent opportunity to study the distinctiveness of HBV, its disease biology in variegated ethnic groups. The North-East India, having international frontiers on three sides, is one of the most ethnically and linguistically diverse region of the country. Given the paucity of information on molecular epidemiology of HBV in this region, the study aimed to carry out an in-depth genetic characterization of HBV prevailing in North-East state of Tripura.

Methods: From sera of chronically HBV infected patients biochemical/serological tests, HBV DNA quantification, PCR-amplification, sequencing of PreS/S or full-length HBV genomes were done. HBV genotype/subgenotype determination and sequence variability were assessed by MEGA5-software. The evolutionary divergence times of different HBV subgenotypes were estimated by DNAMLK/PHYLIP program while jphMM method was used to detect any recombination event in HBV genomes.

Results: HBV genotypes D (89.5%), C (6.6%) and A (3.9%) were detected among chronic carriers. While all HBV/A and HBV/C isolates belonged to subgenotype-A1 and C1 respectively, five subgenotypes of HBV/D (D1–D5) were identified including the first detection of rare D4. These non-recombinant Indian D4 (IndD4) formed a distinct phylogenetic clade, had 2.7% nucleotide divergence and recent evolutionary radiation than other global D4. Ten unique amino acids and 9 novel nucleotide substitutions were identified as IndD4 signatures. All IndD4 carried T120 and R129 in ORF-S that may cause immune/vaccine/diagnostic escape and N128 in ORF-P, implicated as compensatory Lamivudine resistance mutation.

Conclusions: IndD4 has potential to undermine vaccination programs or anti-viral therapy and its introduction to North-East India is believed to be linked with the settlement of ancient Tibeto-Burman migrants from East-Asia.

Introduction

The striking genetic heterogeneity displayed by HBV result mostly from copy errors introduced by viral polymerase during replication of its DNA genome through reverse transcription of pregenomic RNA [1]. However, the long-term fate of these abundant genetic changes depend upon the interactions of HBV with its host, the dramatic intra-host diversification and on different genetic processes such as selection, recombination, genetic drift, population dynamics, and biogeography [1]. Comparisons of HBV sequences from different geographical regions revealed the presence of ten genotypes (A–J), defined by genome dissimilarity by more than 7.5% and most genotypes further segregate into subgenotypes that differ from each other by 4–7.5% [1]. Among them, Genotype D (HBV/D) is most widespread and comprised of 9 subgenotypes (D1–D9), of which

Citation: Banerjee P, Mondal RK, Nandi M, Ghosh S, Khatun M, et al. (2014) A Rare HBV Subgenotype D4 with Unique Genomic Signatures Identified in North-Eastern India –An Emerging Clinical Challenge? PLoS ONE 9(10): e109425. doi:10.1371/journal.pone.0109425

Editor: Ranjit Ray, Saint Louis University, United States of America

Received July 23, 2014; Accepted August 31, 2014; Published October 8, 2014

Copyright: © 2014 Banerjee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files. The sequences of Indian HBV subgenotype D4 reported here are submitted to GenBank (accession numbers: KF192830–KF192841). Additionally 15 full-length reference sequences of HBV/D4 used in this study and indicated in supplementary table 1 have the GenBank accession numbers: FJ692532,FJ692533,FJ692536,AJ627219,AB048701,AB048702,AB048703,AB033559,HE974372,HE974373,HE974378,HE974382,GQ922003,GQ922004,GQ922005.

Funding: This work was supported by the Indian Council of Medical Research, NER/2/2008-ECD-I [B]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: seemdatt@gmail.com

Supporting Information files. The sequences of Indian HBV subgenotype D4 reported here are submitted to GenBank (accession numbers: KF192830 -KF192841). Additionally 15 full-length reference sequences of HBV/D4 used in this study and indicated in supplementary table 1 have the GenBank accession numbers: FJ692532,FJ692533,FJ692536,AJ627219,AB048701,AB048702,AB048703,AB033559,HE974372,HE974373,HE974378,HE974382,GQ922003,GQ922004,GQ922005.
D1–D3 appear worldwide while D4–D9 have a more restricted distribution [1,2].

HBV infection is extremely common in India that is remarkable for its rich population genomic diversity [3]. Taking into consideration the parallelism between HBV-host co-evolution, the diverse Indian population provides an excellent opportunity to study the underpinnings of HBV diversity and disease biology. Of the three genotypes of HBV, D, A and C found in India, HBV/D is predominant and five D-subgenotypes, D1, D2, D3, D5 and D9 had been reported with different local distributions [1,3]. However, there is very limited information on molecular epidemiology of HBV from North-East (N-E) India that has always been a hotspot for population geneticists due to the presence of linguistically, culturally and demographically varied population. Owing to its strategic geographic location, being hemmed in by countries like China, Myanmar, Bhutan and Bangladesh on three sides, the N-E region serve as a gateway connecting India to East/South-East Asia and had been a corridor of extensive human migration in the past. Moreover, studies on N-E Indian populations indicated that their mitochondrial DNA and Y-chromosome gene pools show closer genetic affinities with East/South-East Asian groups than with mainland Indian population [4].

Seven contiguous States (Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland and Tripura) make up the N-E part of the country of which Tripura is the smallest state with a population of about 36.71 lakhs (2011 census). It had a predominant tribal population in the past but the huge wave of immigration from neighboring Bangladesh in post-independence era had resulted in its demographic transformation rendering its indigenous tribal population to a minority [5]. Hepatitis B positivity has been found to be about 4% in Tripura [6]. We initiated the present study to assess the distribution of viral genotypes/subgenotypes in chronically HBV infected patients of Tripura and in the process report for the first time the presence of subgenotype D4 in India and the emergence unique molecular signatures in these isolates that distinguished them from previously reported D4 strains and results in their separate clustering as a new clade that we designate as Indian D4 (IndD4).

### Materials and Methods

#### Collection of blood samples

Five millilitre blood was collected with informed written consent from seventy six treatment-naı­ve chronically HBV infected patients reporting at Agartala Government Medical College, Agartala, Tripura, between 2010 to 2012. Patients with other viral infections and history of significant alcohol intake were excluded. The serum was separated and stored at −80°C until use. The study was approved by Ethical Review Committee of Agartala Government Medical College, Agartala, Tripura.

#### Testing of serological markers and liver enzymes

Each serum sample was tested for the levels of liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using commercially available kits from Bayer Diagnostics (India) in a semiautomated biochemistry analyzer (RA-50; Bayer). The normal ranges for AST and ALT are 2 to 45 IU/liter and 2 to 40 IU/liter, respectively. Serological markers for hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) and antibodies to HBeAg (anti-HBeAg) were also checked in each sample, using commercially available enzyme-linked immunosorbent assay (ELISA) kits from General Biologicals, Taiwan, and bioMe’rieux, Boxtel, Netherlands.

### HBV DNA isolation and quantification

HBV DNA was extracted from 200 μl sera using QIAamp DNA Mini kit (Qiagen Inc., Valencia, CA). Viral DNA titer was

| Table 1. Primers used in this study. |
|-------------------------------------|
| **Primer Name** | **Primer sequence** | **Location [nt]** |
| F1 | 5’-CACAAGAGGACTCTTGAGCT-3’ | 1653–1672 |
| F3 | 5’-CGCTCATTCTTGCTGCT-3’ | 2801–2820 |
| F4 | 5’-CTCAGCGCATGACGGGAA-3’ | 3164–3182 |
| F5 | 5’-GATGTGTCTGCGGCTTGT-3’ | 376–395 |
| F7 | 5’-TGTCACCTGTGCTACCTC-3’ | 1578–1597 |
| F8 | 5’-ATTGTGATCCTCTGGAGACC-3’ | 2746–2767 |
| F10 | 5’-GACCCAAAATGGCCCTATC-3’ | 2298–2317 |
| R1 | 5’-CCACCTTATGAGTCCAAGG-3’ | 2457–2475 |
| R2 | 5’-AAATTACCCACCACCCAGG-3’ | 2109–2127 |
| R3 | 5’-AACTGGAGCCACCGAGCAG-3’ | 57–74 |
| R5 | 5’-AAAGCCCAAAAAGACCCCAAAT-3’ | 996–1016 |
| R8 | 5’-CTTTGACAAACTTTCCAATCAAT-3’ | 973–995 |
| R9 | 5’-TAGGAGTTCCGAGATGAGGA-3’ | 1265–1284 |
| SP2 | 5’-GTATGAGGAGTGAACAA-3’ | 2039–2058 |
| MP1 | 5’-GAGCCCTTCTTTTCCCTCTGCTAAATCA-3’ | 1821–1841 |
| MP2 | 5’-GAGCCCTTCCAAAGATTGTCTATGCTGG-3’ | 1806–1825 |
| P19 | 5’-CCGAAAGCTTGGACTCTTCTTTTCCCTCTGCTCAATCA-3’ | 1821–1841 |
| P29 | 5’-CCGAAAGCTTGGAAGCTCTTGGCTCCAA-3’ | 1823–1806 |

** = nucleotide [nt] positions are given according to HBV sequence with accession no. AF121242 obtained from GenBank.

*Gunther S et al. J. Virol. 1995; 69: 5437–44.*
determined by real time PCR using Roche Diagnostics Cobas Taqman 48 (Roche Diagnostics Molecular Systems, Alameda, CA) and the lower limit of detection was 20 IU/ml.

Amplification and sequencing of HBV genome

The preS1/preS2/S region of HBV was amplified from each sample by PCR using primers F8 and R9 (Table 1) while for samples with low viral load, a second round of amplification with nested primer pair F3 and R9 was performed. Similarly, amplification of basal core promoter (BCP) and Precore (PC) region of HBV was carried out with primer pairs F7-R2 and F1-SP2 (Table 1) in single or two-step nested PCR reactions as appropriate. From selected samples full length HBV DNA was amplified with primers P1 and P2 (Table 1). In case of low HBV DNA level, a second round nested PCR was subsequently performed using two different primer sets, Mp1 with R5 and F3 with MP2 [1]. All PCR products were purified by the QIA quick Gel Extraction Kit (Qiagen, CA) and the nucleotide sequences were determined using BigDye terminator cycle sequencing kit (AB Applied Biosystems, Foster City, CA) on automated DNA sequencer (ABI Prism 3130). DNA sequence editing and analysis were performed using Seqscape V2.5 (Applied Biosystems) software.

Phylogenetic analyses of HBV sequences and estimation of divergence time

To determine HBV genotype/subgenotype, preS/S as well as full-length HBV sequences obtained in the study were compared with representative sequences of 10 genotypes (A–J) as well as that of subgenotypes of A (A1–A7), C (C1–C16) and D (D1–D9) retrieved from GenBank. Sequence alignments were carried out using CLUSTAL_X software and phylogenetic trees were constructed by neighbour-joining method using Kimura 2 parameter model in MEGA software version-5 (www.megasoftware.net). To confirm the reliability of phylogenetic tree analysis, bootstrap resampling and reconstruction were carried out 5000 times. Sequence variability was analyzed with the help of multiple alignment data. The evolutionary relationship between the non-recombinant D-subgenotypes (D1 to D7) was examined using a likelihood method of the DNAMLK program of PHYLIP package (http://evolution.genetics.washington.edu/phylip.html), which uses a ‘molecular clock’ assumption.

Investigation of Recombination events

To detect recombination events in HBV genome sequences, a circular version of jumping profile hidden Markov model (jpHMM) available online at http://jphmm.gobics.de/submission_hbv.htm was used as described previously [1].

Statistical analysis

The data were analyzed in GraphPad PRISM v5 software. The results were presented as median (range) or mean± standard deviation (SD) as applicable. For comparison of quantitative variable, one-way ANOVA or the Mann-Whitney tests were used and for all tests performed, a p-value <0.05 was considered as significant.
Results

Distribution of HBV genotypes and subgenotypes in Tripura

The phylogenetic analysis of 76 PreS/S sequences of HBV from chronic carriers of Tripura revealed the presence of three distinct genotypes; D, C and A. Sixty eight HBV isolates (89.5%) belonged to genotype D, 5 (6.6%) were of genotype C and 3 (3.9%) clustered with genotype A (figure not shown). While all the HBV/A and HBV/C isolates belonged to subgenotype A1 and C1 respectively, genotype D strains were found to be most divergent and segregated into 5 distinct subgenotypes. Thirty six of 68 HBV/D (52.94%) were found to cluster with subgenotype D3, 14 isolates (20.59%) were grouped in D2, 4 (5.88%) belonged to D1 and one (1.47%) to D5. Notably, the remaining 13 HBV/D sequences (19.1%) formed a separate clade within subgenotype D4 (Figure S1). HBV/D4 was not previously reported from any part of India and for a more detailed analysis of these strains, complete genome amplification and sequencing was successfully done in 12 D4-isolates. The phylogenetic tree constructed on basis of these full-length sequences once again placed the IndD4 strains in a separate clade within D4-subgenotype cluster, the branching being supported by high bootstrap value (Figure 1). The estimated intergroup nucleotide divergence (mean ± SD) between IndD4 and other global D4 sequences was found to be 2.7% while it was between 4% −5.2% with respect to other D-subgenotypes (Table 2). Moreover, none of the 12 HBV/D4 showed any evidence of recombination in their genome as determined by jPHMM method (data not shown). We examined the evolutionary relationships between IndD4 and other non-recombinant D-subgenotypes (D1–D7) and in our likelihood estimation of the tree (Figure 2), almost all representative strains were grouped according to their subgenotypes. The only exception was the sequence V01460, which was placed outside the D3 group and used as an outgroup to root the tree. The branching event showed that IndD4 was significantly distant and evolutionary more recent than D4 from other parts of the globe.

Signature residues of HBV/IndD4 in different ORFs and regulatory regions

Prior to this study, a total of 15 full-length sequences of HBV/D4 were available in GenBank (Table S1). We compared the deduced amino acid sequences of all four overlapping open reading frames (ORFs), namely pre-S1/pre-S2/S, X, pre-C/C and P in all 12 IndD4 isolates with the existing D4 sequences as well as with other D-subgenotypes (D1–D9) to identify signature motifs of IndD4. IndD4 differed from the global HBV/D4 by 19 amino acid residues of which 12 residues were found in P ORF, one each in preS1, preS2 and preC/C region and two each in S and X ORFs (Table 3). Of these 19 residues, 10 residues namely T120 in S region, L11 in X ORF, N127 and E250 in the terminal protein (tp) region, F39 and A52 in spacer region (sp), N128, L267 and Q35 in reverse transcriptase (rt) domain and F20 in ribonuclease H (rh) region of ORF P are unique to IndD4, i.e., are not shared or exhibited by the other D-subgenotypes (Table 3) and can be considered as molecular signatures of IndD4.

It is noteworthy that T120 and R129 in S region, found in all IndD4 isolates (Table 3), are two reported HBV mutations with the potential to escape neutralization by vaccine induced antibody [7,8] while N128 in rt domain of ORF P has been implicated as a compensatory or secondary mutation which could increase the viral fitness of HBV when exists in association with primary drug resistance mutation against Lamivudine [9].

The expression of HBV genes is controlled by four different promoters, two enhancers [EnhI [nt. 1074–1234] and EnhII [nt. 1636–1741], a negative regulatory element [NRE; nt. 1613–1636] and posttranscriptional regulatory elements [PRE] [nt. 1151–1684]. Novel nucleotide polymorphisms have been perceived in all IndD4 isolates, two (A3021G and C3033T) in preS2 promoter, one (A1126C) in EnhI and three (1310T, 1405T and 1407A) in PRE that were not seen in any of the D-subgenotypes (D1–D9) (Table 4).

Biochemical and virological characteristics of infection with IndD4 in comparison with other D-subgenotypes

We compared the clinical and virological characteristics of subjects infected with HBV subgenotypes D1-IndD4, while excluding the single patient carrying D3. A predominance of chronic HBeAg-negative infection was noted in Tripura where all subjects harboring IndD4 or D3 and 75% with D1 were negative for HBeAg (Table 5). Majority of patients with IndD4 had ALT < 40 IU/L, similar to those with HBV/D2, while AST level as well as HBV viral load was significantly low in IndD4 as compared to other 3 subgenotypes (D1–D3) (p<0.05) (Table 5). Mutations in BCP and PC region of HBV that can decrease or prevent the synthesis of HBeAg were analyzed in different D-subgenotypes of HBV-negative patients. The double mutation (A1762T and G1764A) in BCP was undetected in IndD4 although it was found at a frequency of 33.33% in D1, 8.33% in D2 and 9.09% in D3 isolates. The stop-codon mutation G1896A in PC was noted in 8.33% of each of IndD4 and D2 and in 9.09% of HBV/D3 while it was absent in D1.

Discussion

In the present study we investigated the prevalence of HBV genotypes/subgenotypes among chronically HBV infected patients in the N-E Indian state of Tripura that is geographically remote from the heartland of India but has rich ethnic diversity and cultural heritage. HBV/D was predominant in Tripura, similar to that observed in most parts of India [3], although genotypes C and A were also detected, albeit at much lower frequencies. However, few prior studies from other N-E states indicated that HBV/A was the major genotype in Arunachal Pradesh followed by genotypes C and D [10]; HBV/D was most common in Assam followed by genotypes A and C [11] while in Manipur, the occult HBV from HIV-positive injection drug users belonged mostly to genotype C [12], thereby reflecting a distinct distribution of viral genotypes in different N-E states.

Phylogenetic analysis of HBV/D isolates of Tripura revealed the presence of five D-subgenotypes (D1–D5), the most striking
### Table 2. Estimates of Evolutionary Divergence over Sequence Pairs between HBV/D subgenotypes (D1–D9) and Indian HBV/D4 (IndD4).

|       | D1    | D2    | D3    | D4    | D5    | D6    | D7    | D8    | D9    | IndD4 |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| D1    | 2.5   | 6.0   | 0.2   | 4.1   | 6.0   | 0.3   | 4.2   | 6.0   | 0.3   | 4.0   |
| D2    | 3.0   | 6.0   | 0.3   | 4.6   | 6.0   | 0.3   | 4.5   | 6.0   | 0.3   | 4.3   |
| D3    | 3.6   | 6.0   | 0.3   | 5.2   | 6.0   | 0.3   | 5.1   | 6.0   | 0.3   | 4.1   |
| D4    | 4.5   | 6.0   | 0.3   | 5.9   | 6.0   | 0.3   | 5.7   | 6.0   | 0.3   | 5.4   |
| D5    | 6.0   | 6.0   | 0.3   | 6.0   | 6.0   | 0.3   | 6.0   | 6.0   | 0.3   | 6.0   |
| D6    | 3.0   | 6.0   | 0.3   | 3.9   | 6.0   | 0.3   | 2.6   | 6.0   | 0.3   | 4.6   |
| D7    | 4.5   | 6.0   | 0.3   | 5.2   | 6.0   | 0.3   | 4.1   | 6.0   | 0.3   | 5.5   |
| D8    | 4.5   | 6.0   | 0.3   | 4.1   | 6.0   | 0.3   | 4.6   | 6.0   | 0.3   | 4.1   |
| D9    | 4.3   | 6.0   | 0.3   | 5.5   | 6.0   | 0.3   | 5.2   | 6.0   | 0.3   | 5.9   |

Genetic distances of Indian HBV/D4 (IndD4) with other subgenotypes of D are indicated in bold and the genetic distance between IndD4 and reported D4 is enclosed within a box.

Molecular epidemiology of HBV suggests that it followed modern human since their dispersal from Africa and the genesis of global genetic tapestry of HBV and the emergence of different genotype/subgenotype resulted from multiple founder events that occurred during their long march with their host across the continents [22]. Given that a sizeable percentage of HBV/D sequences was found in individuals of African origin, it is tempting to speculate that D4 might have originated in Africa and had followed the early wave of human migration via a southern route around the coasts of Indian Ocean to South-East Asia and ultimately to Melanesia and Australia [23,24]. The spread of D4 among the Native Americans (including Na-Den’e Indians) might be linked with later migratory events that occurred subsequent to the colonization of East Asia and the northward diffusion of Asian migrants as far as Siberia and their arrival into American continent from the Beringian landmass [25]. The introduction of HBV/D4 in India might be more recent and given its sole presence in N-E India, it could be envisaged that its advent might have been associated with the settlement of proto-Tibeto-Burman people, who are exclusive to this region and had migrated from East Asia [26]. Our analysis of D4 sequences from different geographical regions and calibrating a molecular clock based on observed nucleotide changes suggested that IndD4 diverged more recently than African and Australian isolates, giving credence to our hypothesis of their relatively recent arrival to India. The narrow strip of land that connects the N-E Indian region to the remaining part of India has served as a bottleneck to the dispersal of Tibeto-Burman immigrants who thus remained land-locked in this region and concurrently HBV/D4 might have been circulating and evolving in isolation in this region for many years unnoticed. Tripura is home to a plethora of ethnic groups, most of whom derived their ancestry from Tibet-Burman family and future studies of HBV genotype/subgenotype in these primitive communities can shed more light into the genetic geography of the virus as well as the history and demography of its host and viral transmission between communities.

The multiple episodes of human migration had also been associated with their significant genetic differentiation and by extrapolation, seem to have influenced the evolutionary trajectory of HBV that is reflected in the emergence of unique signature residues across its four ORFs and regulatory regions. By comparing the amino acids of IndD4 with the available global D4 as well as with other D-subgenotypes, we were able to identify 10 signature residues that were exclusive to IndD4. The most clinically relevant residues found in all IndD4 were T<sup>150</sup> and R<sup>152</sup>,
Table 3. Conserved amino acid residues in four open reading frames of Indian HBV/D4 (IndD4) isolates compared with the previously reported residues at the same position in different subgenotypes of D (D1–D9).

| Amino acid position | Amino acids in subgenotypes of HBV/D |
|---------------------|--------------------------------------|
|                     | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 | D9 | IndD4 [n = 12] |
| PreS/S gene         |    |    |    |    |    |    |    |    |    |                |
| PreS1-27*           | T  | T  | T  | T  | T  | T  | T  | T  | H  | T  |
| PreS2-54            | L  | L  | L/P| L/R| P/L| Q/L| L  | S  | L/P| Q  |
| s120**              | P  | P  | P  | P  | P  | P  | P  | P  | P  | T  |
| s129                | Q/R| Q  | Q  | Q  | Q/H| Q  | Q  | Q  | Q  | R  |
| PreC/C gene         |    |    |    |    |    |    |    |    |    |                |
| c159                | P  | P  | P  | P  | P  | P  | P  | P  | T/A/P| T  |
| X-Gene              |    |    |    |    |    |    |    |    |    |                |
| x11                 | P  | P  | P  | P  | P  | P  | P  | P  |     | L  |
| x12                 | A  | A  | A  | A  | A  | A  | A  | A  | A  | A  |
| Polymerase Gene     |    |    |    |    |    |    |    |    |    |                |
| tp87                | D  | D  | D  | D  | D  | D  | D  | D  | D  | N  |
| tp90                | K  | K  | K  | K  | N/Y| K  | K  | K  | K/N| E  |
| sp30*               | H  | H/L| H  | H  | H  | H  | H  | P  | H  | F  |
| sp62                | T  | T  | T  | T  | T  | T  | T  | S  | T  | A  |
| sp66                | P/S| P  | P  | P  | P  | P  | P  | P  | R  | S  |
| rt122               | F/V| F/V| L  | I  | F  | L  | F  | F/H| L/V| F  |
| rt128**             | T  | T  | T  | T  | T  | T  | T  | T  | T  | N  |
| rt267               | Q  | Q  | Q  | H/Y| H  | Q  | H  | H  | Q/H| L  |
| rt333               | K  | K  | K  | K  | K  | K  | K  | K  | K  | O  |
| rh50                | S  | S  | S  | S  | S  | S  | S  | S  | S  | F  |
| rh54                | I  | I  | I  | I  | I  | I  | I  | I  | I/L| V  |
| rh139               | R  | R  | R  | R  | R  | R  | R  | R  | R  | H  |

Unique residues of IndD4 are underlined. The major amino acids are indicated in bold. *The conserved domains of the open reading frame of HBV polymerase are indicated as follows: tp, terminal protein domain; sp, spacer region; rt, reverse transcriptase domain; rh, RNase H region. ** the overlapping surface and polymerase mutations.
Table 4. Signature nucleotide changes in the regulatory regions of Indian HBV/D4 (IndD4) isolates compared with the previously reported residues at the same position in different subgenotypes of D (D1-D9).

| HBV Regulatory region | Nucleotide position | Nucleotide present in HBV/D subgenotypes |
|-----------------------|---------------------|----------------------------------------|
|                       |                     | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 | D9 | IndD4 [n = 12] |
| Enhancer I/X promoter  | 1126                | A  | A  | A  | A  | A  | A  | A  | A  | A  | C             |
|                       | C2 Promoter [nt 2971–3127] | A  | A  | A  | A  | A  | A  | A  | A  | A  | G             |
|                       | 3021                | C  | C  | C  | C  | C  | C  | C  | C  | C  | T             |
| NRE [nt 1613–1636]   | 1633                | A/G| A  | A/G| A/G| A  | A  | A/G| A  | A  | G             |
|                       | 1310                | C  | C  | C  | C  | C  | C  | C  | C  | C  | T             |
|                       | 1321                | A/C| A  | A  | A  | A/G| A  | A/G| A  | A/C| G            |
| PRE [nt 1151–1684]   | 1405                | G  | G  | C  | C  | C  | C  | C  | C  | C  | T             |
|                       | 1407                | G  | G/T| G  | G  | G  | G  | G  | G  | G  | A             |
|                       | 1577                | G  | G  | G  | G  | G  | A  | G  | G  | G  | A             |
|                       | 1633                | A/G| A  | A  | A/G| A  | A  | A/G| A  | A  | G             |

Unique residues of IndD4 are underlined. The major nucleotide substitutions are indicated in bold.

doi:10.1371/journal.pone.0109425.t004

Table 5. Demographic, serological and virological characteristics of HBV/D (D1-IndD4) samples.

| HBV/D subgenotype | D1 [n = 4] | D2 [n = 14] | D3 [n = 36] | IndD4 [n = 13] | p-value [D1, D2, D3 and IndD4] | p-value [D1, D2, D3 group vs IndD4] |
|-------------------|------------|-------------|-------------|----------------|---------------------------------|------------------------------------|
| Age [years], mean ± SD | 41.00 ± 12.70 | 32.77 ± 13.31 | 37.86 ± 12.29 | 30.31 ± 9.49 | 0.3852* | 0.1593 # |
| ALT [IU/l], Median, Range | 59.75 [21.00 – 72.50] | 39.75 [30.00 – 96.10] | 47.05 [15.60 – 145.90] | 38.00 [1800 – 6200] | 0.0069* | 0.005* # |
| AST [IU/l], Median, Range | 38.20 [34.00 – 46.20] | 49.00 [32.10 – 72.00] | 49.85 [17.70 – 110.0] | 32.00 [1000 – 52.00] | 0.0002* | 0.022* # |
| HBV DNA [IU/ml], Median, Range | 2.41 × 10^3 [1.421 – 1.7 × 10^5] | 9.15 × 10^6 [3.4 × 10^5 – 1.7 × 10^7] | 3.09 × 10^4 [79 – 6.9 × 10^5] | 8.6 × 10^1 [20 – 7.99 × 10^2] | 0.0002* | 0.0195 # |
| HBeAg negativity [%] | 75 | 57.14 | 100 | 100 | | |

SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IU, international unit; #Mann-Whitney test p-value; $One-way ANOVA p value; *p-value < 0.05 was considered significant.
doi:10.1371/journal.pone.0109425.t005
Taken together, the relative isolation of Tripura and its ethnic constitution served as a protection against the spread of HBV/IndD4 and may explain its absence in other parts of the country. The study also reiterates the fact the HBV can serve as an ideal surrogate marker to study human population movements and ancestry and can help to unravel many strongly debated topics in human history. Although IndD4 may appear rather innocuous to its carriers owing to low viral load and normal levels of ALT/AST but the presence of unique genetic signatures that favor immune/vaccine escape, drug resistance and long-term persistence in host can make it an emerging clinical challenge with the potential of undermining the success of vaccination programs or anti-viral therapy.

Supporting Information

Figure S1 Phylogenetic tree showing the subgenotypic distribution of 68 HBV strains belonging to genotype D from Tripura. The tree was formed on the basis of PreS/S sequences. The reference sequences of different subgenotypes of D, namely, D1 to D9, retrieved from GenBank are indicated by their accession numbers while HBV/D sequences determined in the present study are indicated by their respective isolate numbers beginning with “TP”.

Table S1 GenBank Accession numbers and country of origin of 15 full length sequences of HBV of subgenotype D4 available prior to the present study.

Acknowledgments

P. Banerjee is supported by a Senior Research Fellowship from Indian Council of Medical Research while M. Nandi and M. Khatun are supported by Senior and Junior Research Fellowships respectively from University Grants Commission (UGC), New Delhi, India. P. Banerjee, R. K. Mondal, M. Nandi and M. Khatun have registered at the West Bengal University of Health Sciences for their Ph.D. degrees. We thank Indian Council of Medical Research for funding this study through project No. NEK/2/2008-ECID-I [8].

Author Contributions

Conceived and designed the experiments: SD P. Bhauvik AC AS SS. Performed the experiments: P. Banerjee RKM MN MK SG NC SB. Analyzed the data: P. Banerjee AR RMD SD. Contributed reagents/materials/analysis tools: SB AS. Wrote the paper: SD P. Banerjee AC P. Bhauvik SB.

References

1. Ghosh S, Banerjee P, Deny P, Mondal RK, Nandi M, et al. (2013) New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBsAg-negative infection in Eastern India. J Viral Hepat 20: 209–210.
2. Zehnder G, Ehrmann E, Gabanelli E, Skhiev R, Lai A, et al. (2012) Spatial and Temporal Dynamics of Hepatitis B Virus D Genotype in Europe and the Mediterranean Basin. PLoS ONE 7: e31798.
3. Datta S (2008) An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol J 5: 3–156.
4. Borkar, Ahmad F, Khan F, Agrawal S (2011) Paleolithic spread of Y-chromosomal lineage of tribes in eastern and northeastern India. Ann Hum Biol 38: 736–746.
5. Kumar C (2009) Migration and refugee issue between India and Bangladesh. Scholar’s Voice: A New Way of Thinking: 64–82.
6. Bhauvik P, Choudhury AR, Sinha P (2011) Combating Hepatitis B: The Triplura Model. Euroasian Journal of Hepato-Gastroenterology: 3:1–41.
7. Ma Q, Wang Y (2012) Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol 84: 190–206.
8. Kamili S (2010) Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants. Anivir Ther 15: 477–485.
9. Pollicino T, Isgro G, Di Stefano R, Ferraro D, Maimone S, et al. (2009) Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Anivir Ther 14: 649–654.
10. Borkakoty BJ, Mahanta J, Biswas D (2008) Circulating genotypes of hepatitis B virus in Arunachal Pradesh. Indian J Med Res 127: 65–70.
11. Deka M, Bose M, Baruah R, Bose PD, Medhi S, et al. (2010) Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India. World J Gastroenterol 16: 4800–4808.
12. Datta S, Banerjee A, Chandra PK, Mahapatra PK, Chakrabarti S, et al. (2006) Drug trafficking routes and hepatitis B in injection drug users, Manipur, India. Emerg Infect Dis 12: 1954–1957.
13. Andermarch JH, Noke C, Pape JW, Muller CP (2009) Slave Trade and Hepatitis B Virus Genotypes and Subgenotypes in Haiti and Africa. Emerg Infect Dis 15: 1222–1228.
14. Kwangs SO, Budambula NL, Kiptoo MK, Okoth F, Ochwoho M, et al. (2013) Hepatitis B virus subgenotype A1, occurrence of subgenotype D4, and S gene mutations among voluntary blood donors in Kenya. Virus Genes 47: 448–455.
15. Candotti D, Opere-Sem O, Rezvan H, Sarkodie F, Allain JP (2006) Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood
donors with and without elevated alanine aminotransferase. J Viral Hepat 13: 715–724.

16. Baha W, Enejai MM, Lazar F, Mellof M, El Fahime E, et al. (2012) HBV genotypes prevalence, precore and basal core mutants in Morocco. Infect Genet Evol 12: 1157–1162.

17. Brichler S, Lagathu G, Chekaraou MA, Le Gal F, Edouard A, et al. (2013) African, Amerindian and European hepatitis B virus strains circulate on the Caribbean Island of Martinique. J Gen Virol 94: 2318–2329.

18. Utsumi T, Yano Y, Truong BX, Tanaka Y, Mizokami M, et al. (2007) Molecular epidemiological study of hepatitis B virus infection in two different ethnic populations from the Solomon Islands. J Med Virol 79: 229–235.

19. Sugauchi F, Mizokami M, Orito E, Ohno T, Kato H, et al. (2001) A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. J Gen Virol 82: 883–892.

20. Osiowy C, Larke B, Giles E (2011) Distinct geographical and demographic distribution of hepatitis B virus genotypes in the Canadian Arctic as revealed through an extensive molecular epidemiological survey. J Viral Hepat 18: e11–9.

21. Santos AO, Alvarado-Mora MV, Botelho L, Vieira DS, Pinho JR, et al. (2010) Characterization of Hepatitis B virus (HBV) genotypes in patients from Rondônia, Brazil. Virol J 7: 315.

22. Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Beldsaw R, et al. (2013) Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 57: 908–916.

23. Fernandes V, Alshamali F, Alves M, Costa MD, Pereira JB, et al. (2012) The Arabian cradle: mitochondrial relics of the first steps along the southern route out of Africa. Am J Hum Genet 90: 347–355.

24. Pugach I, Delfin F, Gunnarsdottir E, Kayser M, Stoneking M (2013) Genome-wide data substantiate Holocene gene flow from India to Australia. Proc Natl Acad Sci U S A 110: 1803–1808.

25. Reich D, Patterson N, Campbell D, Tandon A, Mazieres S, et al. (2012) Reconstructing Native American population history. Nature 488: 370–374.

26. Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, et al. (2003) Ethnic India: a genomic view, with special reference to peopling and structure. Genome Res 13: 2277–2290.

27. Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, et al. (2012) Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol 57: 720–729.

28. Gilles PN, Guerette DI, Ulevitch RJ, Scheibner RD, Chisari FV (1992) HBsAg retention sensitizes the hepatocyte to injury by physiologocal concentrations of interferon-gamma. Hepatology 16: 653–663.

29. Wang HY, Chen MH, Huang HP, Chang HC, Wu CC, et al. (2010) Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 84: 3454–3463.